Market Statistics
Base Year: 2023
Historical Years: 2018-2023
Forecast Years: 2024-2032
Market Growth Rate: 4.1% (2024-2032)
The global cancer cachexia market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.
Industry Trends and Drivers:
- Increasing prevalence of cancer and chronic diseases:
The growing prevalence of cancer and other chronic diseases is a primary factor driving the global cancer cachexia market. Cancer is a leading cause of death worldwide, and its incidence continues to rise due to factors such as aging populations, lifestyle changes, environmental factors, and genetic predisposition. Cachexia, a complex metabolic syndrome characterized by severe weight loss, muscle wasting, and appetite loss, affects up to 80% of cancer patients, particularly in advanced stages of the disease. The high prevalence of cancer directly correlates with the increasing number of patients suffering from cachexia, thereby fueling demand for effective treatments and interventions.
- Advancements in cachexia research and drug development:
Another critical factor propelling the global cancer cachexia market is the advancement in cachexia research and drug development. In recent years, there has been a rise in understanding the complex pathophysiology of cachexia, including its underlying mechanisms involving inflammation, metabolic alterations, and hormonal changes. These insights have paved the way for the development of novel therapeutic approaches targeting specific pathways, such as anti-inflammatory agents, appetite stimulants, and anabolic agents designed to counteract muscle wasting and weight loss. Emerging biotechnologies and innovative drug delivery systems are also contributing to market growth. For instance, advancements in nanotechnology are enabling the development of targeted drug delivery systems that can more effectively deliver cachexia treatments to specific tissues, minimizing side effects and improving patient outcomes. Additionally, the discovery of new biomarkers and genetic targets for cachexia has opened up opportunities for personalized medicine approaches, which are anticipated to revolutionize the way cachexia is managed.
- Increasing focus on quality of life and supportive care:
A growing emphasis on improving quality of life and supportive care for cancer patients is also driving the global cancer cachexia market. Cancer cachexia significantly affects patients’ physical function, emotional well-being, and overall quality of life. It is associated with increased morbidity, reduced tolerance to cancer treatments, and higher mortality rates. As a result, healthcare providers are increasingly prioritizing cachexia management as a crucial aspect of comprehensive cancer care. The growing recognition of cachexia as a key determinant of patient outcomes has led to increased awareness and education efforts among healthcare professionals, patients, and caregivers about the importance of early intervention and multidisciplinary management approaches. Supportive care, which includes nutritional support, physical therapy, psychological counseling, and pharmacological interventions, is becoming an integral part of cancer treatment plans.
For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/cancer-cachexia-market/requestsample
Cancer Cachexia Market Report Segmentation:
Breakup By Therapeutics:
- Progestogens
- Corticosteroids
- Combination Therapy
- Others
Progestogens dominate the market as they are well-established for their effectiveness in stimulating appetite and improving weight gain in cachexia patients.
Breakup By Mode of Action:
- Appetite Stimulators
- Weight Loss Stabilizers
Weight loss stabilizers hold the largest segment due to their effective role in counteracting and managing severe weight loss and muscle wasting associated with cachexia.
Breakup By Distribution Channel:
- Hospital Stores
- Retail Pharmacy
- Online Pharmacy
Based on the distribution channel, the market has been divided into hospital stores, retail pharmacy and online pharmacy.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America holds the leading position owing to a large market for cancer cachexia driven by its advanced healthcare infrastructure, high prevalence of cancer, and significant investment in research and development for cachexia treatments.
Top Cancer Cachexia Market Leaders:
- AAVogen Inc.
- Actimed Therapeutics Ltd.
- Aphios Corporation
- Artelo Biosciences Inc.
- AVEO Pharmaceuticals Inc.
- Fresenius Kabi AG (Fresenius SE & Co. KGaA)
- Helsinn Healthcare SA
- Merck & Co. Inc.
- NGM Biopharmaceuticals Inc.
- Pfizer Inc.
- Tetra Bio-Pharma
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
